Leaders | Never-ending story

Salman Rushdie and the struggle for free speech

A horrific attack shows the old battles still rage

BERLIN, GERMANY - SEPTEMBER 14: Author Salman Rushdie at a press conference on the 13th International Literature Festival at the Haus der Berliner Festspiele on September 14, 2013 in Berlin, Germany. (Photo by Frank Hoensch/Getty Images)

The longer Salman Rushdie remained alive, he wrote in “Joseph Anton”, “the longer he went without being killed, the easier it was for people to believe that nobody was trying to kill him.” The book is a memoir of the years the author spent in hiding after Ayatollah Ruhollah Khomeini, then Iran’s supreme leader, issued a fatwa urging Muslims to murder him and his publishers because of the alleged blasphemy of his novel, “The Satanic Verses”. That was in 1989; on August 12th Sir Salman (as he became in 2007) was stabbed as he was about to give a lecture in upstate New York.

This article appeared in the Leaders section of the print edition under the headline “Never-ending story”

Walkies

From the August 20th 2022 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Leaders

Keir Starmer surrounded by the Eu stars

Sir Keir Starmer should aim higher in his reset with the EU

And he needs to be clearer about what Britain wants

illustration of a world map outlined by a single red electrical cord, with a plug at one end and a socket at the other

To make electricity cheaper and greener, connect the world’s grids

Less than 3% of the world’s power is internationally traded—a huge wasted opportunity


Chinese AI is catching up, posing a dilemma for Donald Trump

The success of cheap Chinese models threatens America’s technological lead


America has an imperial presidency

And in Donald Trump, an imperialist president for the first time in over a century

Tariffs will harm America, not induce a manufacturing rebirth

Donald Trump’s pursuit of tariffs will make the world poorer—and America, too 

How to improve clinical trials

Involving more participants can lead to new medical insights